Alkhateeb Tuqa, Bah Isatou, Kumbhare Ajinkya, Youssef Dima, Yao Zhi Q, McCall Charles E, Gazzar Mohamed El
Department of Internal Medicine, East Tennessee State University College of Medicine, Johnson City, TN 37614, USA.
Department of Internal Medicine, Section of Molecular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
J Clin Cell Immunol. 2020;11(6). Epub 2020 Sep 22.
Myeloid-derived suppressor cells (MDSCs) expand during mouse and human sepsis, but the mechanism responsible for this is unclear. We previously reported that nuclear transport of S100A9 protein programs Gr1CD11b myeloid precursors into MDSCs in septic mice. Here, we show that long non-coding RNA Hotairm1 converts MDSCs from an activator to a repressor state. Mechanistically, increased Hotairm1 expression in MDSCs in mice converted S100A9 from a secreted proinflammatory mediator to an immune repressor by binding to and shuttling it from cytosol to nucleus during late sepsis. High Hotairm1 levels were detected in exosomes shed from MDSCs from late septic mice. These exosomes inhibited lipopolysaccharide-stimulated secretion of S100A9 from early sepsis Gr1CD11b cells. Importantly, Hotairm1 knockdown in late sepsis Gr1CD11b MDSCs prevented S100A9 cytosol to nuclear transfer and decreased repression of proimmune T cells. Notably, ectopic expression of Hotairm1 in early sepsis Gr1CD11b cells shuttled S100A9 to the nucleus and promoted the MDSC repressor phenotype. In support of translating the mechanistic concept to human sepsis, we found that Hotairm1 binds S100A9 protein in CD33CD11bHLA-DR MDSCs during established sepsis. Together, these data support that Hotairm1 is a plausible molecular target for treating late sepsis immune suppression in humans and its immune repressor mechanism may be cell autonomous.
髓源性抑制细胞(MDSCs)在小鼠和人类脓毒症期间会扩增,但其背后的机制尚不清楚。我们之前报道过,在脓毒症小鼠中,S100A9蛋白的核转运将Gr1⁺CD11b⁺髓系前体细胞编程为MDSCs。在此,我们表明长链非编码RNA Hotairm1将MDSCs从激活状态转变为抑制状态。从机制上讲,小鼠MDSCs中Hotairm1表达的增加,通过在脓毒症后期将S100A9从胞质溶胶结合并转运至细胞核,使其从分泌型促炎介质转变为免疫抑制因子。在晚期脓毒症小鼠的MDSCs释放的外泌体中检测到高水平的Hotairm1。这些外泌体抑制了早期脓毒症Gr1⁺CD11b⁺细胞中脂多糖刺激的S100A9分泌。重要的是,晚期脓毒症Gr1⁺CD11b⁺MDSCs中Hotairm1的敲低阻止了S100A9从胞质溶胶向细胞核的转移,并减少了对促免疫T细胞的抑制。值得注意的是,早期脓毒症Gr1⁺CD11b⁺细胞中Hotairm1的异位表达将S100A9转运至细胞核并促进了MDSC抑制表型。为了支持将这一机制概念转化应用于人类脓毒症,我们发现在已确诊的脓毒症期间,Hotairm1在CD33⁺CD11b⁺HLA-DR⁻ MDSCs中与S100A9蛋白结合。总之,这些数据支持Hotairm1是治疗人类晚期脓毒症免疫抑制的一个合理分子靶点,其免疫抑制机制可能是细胞自主的。